Flibanserin (US brand name Addyi®) is a serotonin 1A receptor agonist and a serotonin 2A receptor antagonist. The exact mechanism of action of flibanserin is unknown. Here is basic information about this medication.
FDA-approved indications
Treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to:
- A co-existing medical or psychiatric condition
- Problems within the relationship or
- The effects of a medication or other drug substance
Dosage
Recommended: 100 mg orally taken once daily at bedtime
Discontinue treatment after 8 weeks if no improvement
Contraindications
Alcohol(deleted on April 13, 2019)- Moderate or strong cytochrome P450 3A4 (CYP3A4) inhibitors
- Hepatic impairment
Dosage forms and strengths (USA)
Tablet: 100 mg
Important! Please refer to the full Prescribing Information (see link below) before prescribing this medication.
Related Pages
Flibanserin (Addyi®)
Flibanserin (Addyi®): Systematic list of references
Sexual dysfunction
Arizona Sexual Experiences Scale (ASEX)
References
Prescribing information for flibanserin (Addyi®)
Copyright 2017, Rajnish Mago, MD. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.
Leave a Reply: